{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:32:07Z","timestamp":1761921127279,"version":"3.43.0"},"reference-count":40,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"unspecified","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Solidarity Response Fund NPC","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100000880","name":"Michael and Susan Dell Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100000880","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009041","name":"National Department of Health","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100009041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009977","name":"ELMA Foundation","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100009977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100016979","name":"National Treasury","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100016979","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["bmjmed"],"accepted":{"date-parts":[[2023,2,23]]},"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the rates of vascular thrombotic adverse events in the first 35 days after one dose of the Ad26.COV2.S vaccine (Janssen\/Johnson &amp; Johnson) in healthcare workers in South Africa and to compare these rates with those observed in the general population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Open label, single arm, phase 3B study.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Sisonke study, South Africa, 17 February to 15 June 2021.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>The Sisonke cohort of 477 234 healthcare workers, aged \u226518 years, who received one dose of the Ad26.COV2.S vaccine.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main outcome measures<\/jats:title>\n                  <jats:p>Observed rates of venous arterial thromboembolism and vaccine induced immune thrombocytopenia and thrombosis in individuals who were vaccinated, compared with expected rates, based on age and sex specific background rates from the Clinical Practice Research Datalink GOLD database (database of longitudinal routinely collected electronic health records from UK primary care practices using Vision general practice patient management software).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Most of the study participants were women (74.9%) and median age was 42 years (interquartile range 33-51). Twenty nine (30.6 per 100 000 person years, 95% confidence interval 20.5 to 44.0) vascular thrombotic events occurred at a median of 14 days (7-29) after vaccination. Of these 29 participants, 93.1% were women, median age 46 (37-55) years, and 51.7% had comorbidities. The observed to expected ratios for cerebral venous sinus thrombosis with thrombocytopenia and pulmonary embolism with thrombocytopenia were 10.6 (95% confidence interval 0.3 to 58.8) and 1.2 (0.1 to 6.5), respectively. Because of the small number of adverse events and wide confidence intervals, no conclusions were drawn between these estimates and the expected incidence rates in the population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Vaccine induced immune thrombocytopenia and thrombosis after one dose of the Ad26.COV2.S vaccine was found in only a few patients in this South African population of healthcare workers. These findings are reassuring if considered in terms of the beneficial effects of vaccination against covid-19 disease. These data support the continued use of this vaccine, but surveillance is recommended to identify other incidences of venous and arterial thromboembolism and to improve confidence in the data estimates.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration<\/jats:title>\n                  <jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"NCT04838795\">NCT04838795<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjmed-2022-000302","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T11:06:33Z","timestamp":1680519993000},"page":"e000302","source":"Crossref","is-referenced-by-count":5,"title":["Vascular thrombosis after single dose Ad26.COV2.S vaccine in healthcare workers in South Africa: open label, single arm, phase 3B study (Sisonke study)"],"prefix":"10.1136","volume":"2","author":[{"given":"Barry Frank","family":"Jacobson","sequence":"first","affiliation":[{"name":"Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise","family":"Schapkaitz","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azwi","family":"Takalani","sequence":"additional","affiliation":[{"name":"Hutchinson Centre Research Institute of South Africa (HCRISA), Chris Hani Baragwanath Hospital, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Rowji","sequence":"additional","affiliation":[{"name":"The Southern African Society of Thrombosis and Haemostasis, Neurology Association of South Africa, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vernon Johan","family":"Louw","sequence":"additional","affiliation":[{"name":"Division of Clinical Haematology, Department of Medicine, Faculty of Health Sciences, University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Opie","sequence":"additional","affiliation":[{"name":"Division of Haematology, Department of Pathology, University of Cape Town and National Health Laboratory Service, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda-Gail","family":"Bekker","sequence":"additional","affiliation":[{"name":"Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nigel","family":"Garrett","sequence":"additional","affiliation":[{"name":"Centre for the AIDS Programme of Research in South Africa, Durban, South Africa"},{"name":"Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ameena","family":"Goga","sequence":"additional","affiliation":[{"name":"HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa"},{"name":"Paediatrics and Child Health, University of Pretoria, Pretoria, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarylee","family":"Reddy","sequence":"additional","affiliation":[{"name":"Biostatistics Research Unit, South African Medical Research Council, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nonhlanhla","family":"Yende-Zuma","sequence":"additional","affiliation":[{"name":"Nelson R Mandela School of Medicine, Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Sanne","sequence":"additional","affiliation":[{"name":"Clinical HIV Research Unit, University of the Witwatersrand Faculty of Sciences, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ishen","family":"Seocharan","sequence":"additional","affiliation":[{"name":"Biostatistics Research Unit, South African Medical Research Council, Durban, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonny","family":"Peter","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa"},{"name":"Allergy and Immunology Unit, University of Cape Town Lung Institute, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Robinson","sequence":"additional","affiliation":[{"name":"Right To Care, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley","family":"Collie","sequence":"additional","affiliation":[{"name":"Discovery Health, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9950-0464","authenticated-orcid":false,"given":"Amber","family":"Khan","sequence":"additional","affiliation":[{"name":"Molecular Medicine and Haematology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simbarashe","family":"Takuva","sequence":"additional","affiliation":[{"name":"School of Health Systems and Public Health, University of Pretoria, Faculty of Health Sciences, Pretoria, South Africa"},{"name":"Perinatal HIV Research Unit, University of the Witwatersrand, Faculty of Health Sciences, Johannesburg, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenda","family":"Gray","sequence":"additional","affiliation":[{"name":"HIV and Other Infectious Diseases Research Unit, South African Medical Research Council, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"2025080500590427000_2.1.e000302.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2117608"},{"key":"2025080500590427000_2.1.e000302.2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00947-8"},{"key":"2025080500590427000_2.1.e000302.3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"2025080500590427000_2.1.e000302.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMOA2113017\/SUPPL_FILE\/NEJMOA2113017_DATA-SHARING.PDF"},{"key":"2025080500590427000_2.1.e000302.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577"},{"key":"2025080500590427000_2.1.e000302.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102742"},{"key":"2025080500590427000_2.1.e000302.7","unstructured":"European Medicines Agency . COVID-19 vaccine safety update. vaxzevria 2021. Amsterdam, The Netherlands: EMA, 2021."},{"key":"2025080500590427000_2.1.e000302.8","unstructured":"European Medicines Agency . News: astrazeneca\u2019s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. Amsterdam, The Netherlands: EMA, 2021."},{"key":"2025080500590427000_2.1.e000302.9","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00956-2021","article-title":"Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from vigibase","volume":"58","author":"Smadja","year":"2021","journal-title":"Eur Respir J"},{"key":"2025080500590427000_2.1.e000302.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102685"},{"key":"2025080500590427000_2.1.e000302.11","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1056\/NEJMoa2104882","article-title":"Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"384","author":"Schultz","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080500590427000_2.1.e000302.12","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1001\/jama.2021.7517","article-title":"US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination, March 2 to April 21, 2021","volume":"325","author":"See","year":"2021","journal-title":"JAMA"},{"key":"2025080500590427000_2.1.e000302.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n699"},{"key":"2025080500590427000_2.1.e000302.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2104840"},{"key":"2025080500590427000_2.1.e000302.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2105385"},{"key":"2025080500590427000_2.1.e000302.16","unstructured":"Brighton Collaboration . Interim case definition of thrombosis with thrombocytopenia syndrome (TTS). 2021. Available: https:\/\/brightoncollaboration.us\/thrombosis-with-thrombocytopenia-syndrome-interim-case-definition\/Date [Accessed 23 Sep 2022]."},{"key":"2025080500590427000_2.1.e000302.17","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMoa2109908","article-title":"Clinical features of vaccine-induced immune thrombocytopenia and thrombosis","volume":"385","author":"Pavord","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080500590427000_2.1.e000302.18","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7017e4"},{"key":"2025080500590427000_2.1.e000302.19","unstructured":"European Medicines Agency . EudraVigilance: European database of suspected adverse drug reaction reports. Amsterdam, The Netherlands: EMA. 2021. Available: www.adrreports.eu\/en\/background.html [Accessed Apr 2021]."},{"key":"2025080500590427000_2.1.e000302.20","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMc2107920","article-title":"Thromboembolic events in the south african ad26.COV2.S vaccine study","volume":"385","author":"Takuva","year":"2021","journal-title":"N Engl J Med"},{"key":"2025080500590427000_2.1.e000302.21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004024","article-title":"Safety evaluation of the single-dose ad26.COV2.S vaccine among healthcare workers in the sisonke study in South Africa: a phase 3B implementation trial","volume":"19","author":"Takuva","year":"2022","journal-title":"PLoS Med"},{"key":"2025080500590427000_2.1.e000302.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(02)00449-8"},{"key":"2025080500590427000_2.1.e000302.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1411910"},{"key":"2025080500590427000_2.1.e000302.24","first-page":"535","article-title":"Recommendations for the diagnosis and management of vaccine-induced immune thrombotic thrombocytopenia","volume":"111","author":"Jacobson","year":"2021","journal-title":"S Afr Med J"},{"key":"2025080500590427000_2.1.e000302.25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V67.1.27.27","article-title":"A diagnostic test for heparin-induced thrombocytopenia","volume":"67","author":"Sheridan","year":"1986","journal-title":"Blood"},{"key":"2025080500590427000_2.1.e000302.26","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1111\/jth.15341","article-title":"Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: communication from the ISTH SSC Subcommittee on platelet immunology","volume":"19","author":"Nazy","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025080500590427000_2.1.e000302.27","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyv098"},{"key":"2025080500590427000_2.1.e000302.28","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz034"},{"key":"2025080500590427000_2.1.e000302.29","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5419"},{"key":"2025080500590427000_2.1.e000302.30","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1111\/jth.13769","article-title":"Epidemiology of venous thromboembolism in Africa: a systematic review","volume":"15","author":"Danwang","year":"2017","journal-title":"J Thromb Haemost"},{"key":"2025080500590427000_2.1.e000302.31","doi-asserted-by":"publisher","DOI":"10.1055\/a-1366-9656"},{"key":"2025080500590427000_2.1.e000302.32","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29721","article-title":"Pulmonary embolism in pediatric and adolescent patients with COVID-19 infection during the SARS-cov-2 delta wave","volume":"69","author":"Cohen","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"2025080500590427000_2.1.e000302.33","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-022-07421-3","article-title":"Venous thromboembolism in COVID-19 patients and prediction model: a multicenter cohort study","volume":"22","author":"Lee","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025080500590427000_2.1.e000302.34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ejvs.2020.12.015","article-title":"COVID-19 infection in critically ill patients carries a high risk of venous thrombo-embolism","volume":"61","author":"Bellmunt-Montoya","year":"2021","journal-title":"Eur J Vasc Endovasc Surg"},{"key":"2025080500590427000_2.1.e000302.35","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2020-215383"},{"key":"2025080500590427000_2.1.e000302.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.11.005"},{"key":"2025080500590427000_2.1.e000302.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00542-4"},{"key":"2025080500590427000_2.1.e000302.38","unstructured":"WHO international- News Room feature stories. The Janssen Ad26.COV2.S COVID-19 vaccine: What you need to know. 2022. Available: www.who.int\/news-room\/feature-stories\/detail\/the-j-j-covid-19-vaccine-what-you-need-to-know"},{"key":"2025080500590427000_2.1.e000302.39","doi-asserted-by":"publisher","DOI":"10.1177\/1747493020972922"},{"key":"2025080500590427000_2.1.e000302.40","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00007-1"}],"container-title":["BMJ Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjmed-2022-000302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T07:59:15Z","timestamp":1754380755000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjmedicine.bmj.com\/lookup\/doi\/10.1136\/bmjmed-2022-000302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,3,24]]},"published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1136\/bmjmed-2022-000302"],"URL":"https:\/\/doi.org\/10.1136\/bmjmed-2022-000302","relation":{},"ISSN":["2754-0413"],"issn-type":[{"type":"electronic","value":"2754-0413"}],"subject":[],"published":{"date-parts":[[2023,3]]}}}